STAT3 and graft versus host disease: Prior work showed that anti-CD25–mediated Treg depletion reversed protection from Stat3 deficiency in a mouse model of chronic sclerodermatous GVHD, where anti-CD25 treatment resulted in delayed, organ-specific GVHD in recipients of Stat3-deficient T cells (3).